[HTML][HTML] Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: a review
Y Guo, J Song, Y Wang, L Huang, L Sun, J Zhao… - Frontiers in …, 2020 - frontiersin.org
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …
survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR …
[HTML][HTML] Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
AL Désage, C Léonce, A Swalduz… - Frontiers in …, 2022 - frontiersin.org
Although KRAS-activating mutations represent the most common oncogenic driver in non-
small cell lung cancer (NSCLC), various attempts to inhibit KRAS failed in the past decade …
small cell lung cancer (NSCLC), various attempts to inhibit KRAS failed in the past decade …
Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors
S Ortiz-Cuaran, M Scheffler, D Plenker, L Dahmen… - Clinical Cancer …, 2016 - AACR
Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in
patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or …
patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or …
[HTML][HTML] mTOR pathway: A current, up-to-date mini-review
P Zarogoulidis, S Lampaki, JF Turner… - Oncology …, 2014 - spandidos-publications.com
Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially
identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation …
identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation …
[HTML][HTML] MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes
Recurrent mutations in the myogenic transcription factor MYOD1 and PIK3CA were initially
described in a subset of embryonal rhabdomyosarcomas. Recently, two independent …
described in a subset of embryonal rhabdomyosarcomas. Recently, two independent …
[HTML][HTML] Contribution of KRAS mutations and c. 2369C> T (p. T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor …
M Del Re, M Tiseo, P Bordi, A D'Incecco, A Camerini… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Aim The aim of this study was to investigate the appearance of MUT KRAS during EGFR-TKI
treatment and their contribution to drug resistance. Methods This study used cell-free …
treatment and their contribution to drug resistance. Methods This study used cell-free …
[HTML][HTML] The presence of concomitant mutations affects the activity of EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC) patients
AM Rachiglio, F Fenizia, MC Piccirillo, D Galetta… - Cancers, 2019 - mdpi.com
Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers
(NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR …
(NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR …
Targeting KRASp. G12C mutation in advanced non-small cell lung cancer: a new era has begun
M Bungaro, S Novello, F Passiglia - Current Treatment Options in …, 2022 - Springer
Opinion statement KRASp. G12C mutation occurs in 12% of newly diagnosed advanced
NSCLC and has recently emerged as a positive predictive biomarker for the selection of …
NSCLC and has recently emerged as a positive predictive biomarker for the selection of …
[HTML][HTML] Pleural involvement in lung cancer
T Agalioti, AD Giannou… - Journal of thoracic …, 2015 - ncbi.nlm.nih.gov
The pleural space, a sterile secluded environment in the thoracic cavity, represents an
attractive metastatic site for various cancers of lung, breast and gastrointestinal origins …
attractive metastatic site for various cancers of lung, breast and gastrointestinal origins …
[HTML][HTML] Characteristics and outcomes of patients with lung cancer harboring multiple molecular alterations: results from the IFCT study biomarkers France
N Guibert, F Barlesi, R Descourt, H Léna… - Journal of Thoracic …, 2017 - Elsevier
Introduction Little is known about the prevalence, prognosis, and response to treatment of
advanced NSCLC harboring multiple genomic alterations. Methods The French Biomarkers …
advanced NSCLC harboring multiple genomic alterations. Methods The French Biomarkers …